Good News for Patients with Strep

SEPTEMBER 01, 2006
Susan Farley

The Amoxicillin PULSYS Phase III Trial achieved its clinical goals in the treatment of adults and adolescents with pharyngitis/tonsillitis due to Group A streptococcal infections (strep throat). Advancis Pharmaceutical Corp enrolled 620 adults and adolescents in a randomized, double-blind, multicenter, noninferiority trial in November 2005. Researchers compared the once-daily, 775-mg tablet of Amoxicillin PULSYS for 10 days with 250 mg of penicillin VK 4 times a day for 10 days. The primary desired end point of the trial was bacterial eradication at the "test-of-cure" visit for patients who had completed the protocol, measured by throat cultures before and after treatment. Bacterial eradication at the posttherapy test-of-cure visit among the patients who had completed the protocol was 85% in the Amoxicillin PULSYS group and 83.4% with penicillin. Stan L. Block, MD, an investigator in the study and a professor of clinical pediatrics noted, "The outcomes were achieved through a single-daily-dose administration, a significant factor with the potential to positively impact patient compliance."

Ms. Farley is a freelance medical writer based in Wakefield, RI.


The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


Pharmacy Times Strategic Alliance

Conference Coverage
News from the year's biggest meetings

Pharmacist Education
Clinical features with downloadable PDFs


Personalize the information you receive by selecting targeted content and special offers.